Improving Outcomes for Patients with Psoriatic Arthritis: Integrating a Comprehensive, Patient-Centered Care Model into Your Practice

Improving Outcomes for Patients with Psoriatic Arthritis (PsA): Integrating a Comprehensive, Patient-Centered Care Model into Your Practice is organized by CME Outfitters, LLC.

Premiere Date: Monday, May 4, 2020
Credit Expiration Date: Tuesday, May 4, 2021

This activity offers CE credit for:
• Physicians (CME)
• Pharmacists (ACPE)
• ABIM (MOC)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Information:
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.75 contact hours (0.075 CEUs)

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Note to PAs: PAs may claim a maximum of .75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Statement of Need:
Psoriatic arthritis (PsA), a serious and potentially disabling condition, affects approximately 30% of patients with psoriasis, with the joint involvement often occurring about 10 years after the appearance of skin disease. PsA causes not only physical and functional impairments but also has a negative impact on overall quality of life. While dermatologists have an important role in early detection of PsA, patients often have overlapping treatment needs that require collaborative care between dermatologists and rheumatologists.

Recent U.S. Food and Drug Administration (FDA) approvals of several agents for moderate-to-severe PsA have expanded the treatment armamentarium, and the management paradigm continues to evolve. However, PsA continues to be under-recognized, misdiagnosed, and inadequately treated.

In this CMEOCast podcast, expert faculty focus on the latest evidence on screening patients for PsA, individualizing treatment that considers patient-reported outcomes (PROs), and using patient-centered approaches for care, with the goal of optimizing patient outcomes.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Employ screening and assessment strategies to diagnose patients with PsA in clinical practice.
• Integrate clinical evidence for targeted therapies when individualizing treatment for patients with PsA, including their effects on PROs.
• Implement comprehensive, multidisciplinary, patient-centered approaches to treating PsA, taking into account patient preference and presence of comorbidities.
The following learning objectives pertain only to those requesting CNE or CPE credit:
• Summarize screening and assessment strategies to diagnose patients with PsA in clinical practice.
• Describe clinical evidence for targeted therapies when individualizing treatment for patients with PsA, including their effects on PROs.
• Explain comprehensive, multidisciplinary, patient-centered approaches to treating PsA, taking into account patient preference and presence of comorbidities.